
ESSA Pharma Investor Relations Material
Latest events

AGM 2024
ESSA Pharma

Q2 2025
8 May, 2025

Q1 2025
11 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ESSA Pharma Inc
Access all reports
ESSA Pharma Inc. is a clinical-stage pharmaceutical company primarily focused on the development of novel therapies for the treatment of prostate cancer. The company is pioneering the creation of a new class of drugs known as "anitens," which are designed to disrupt the androgen receptor signaling pathway, a key driver in the progression of prostate cancer. ESSA's lead clinical candidate, masofaniten (formerly known as EPI-7386), targets the N-terminal domain of the androgen receptor, aiming to offer a novel approach for patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, especially those who have developed resistance to current anti-androgen therapies. The company is headquartered in Vancouver, Canada, and its shares are listed on the Nasdaq.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
EPIX
Country
🇺🇸 United States